Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers Health Inc. reported strong first-quarter results Monday, beating analyst expectations for both revenue and ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results tomorrow after the bell. Here’s what investors ...

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 66.67% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...